Company Overview of Helocyte Inc.
Helocyte Inc. engages in the development and commercialization of immunotherapies for the prevention and treatment of cytomegalovirus or CMV (cancer and infectious disease). It focuses on developing PepVax, a HLA-restricted single antigen peptide vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant recipients; and Triplex, a universal recombinant viral vector vaccine expressing three immuno-dominant proteins, such as UL83 (pp65), UL123 (IE1), and UL122 (IE2) linked to CMV in the post-transplant setting; and Pentamer, a universal recombinant viral vector vaccine designed to induce a neutralizing antibody response to prevent the transmission of CMV from mother to fetus....
2 Gansevoort Street
New York, NY 10014
Founded in 2015
Key Executives for Helocyte Inc.
Co-Founder, Chief Executive Officer, President and Director
Executive Chairman of The Board of Directors
Co-Founder and Chairman of Scientific Advisory Board
Interim Chief Financial Officer
Executive Vice President of Regulatory Affairs
Compensation as of Fiscal Year 2017.
Helocyte Inc. Key Developments
Helocyte Inc. Presents at Aegis Capital Corp. 2016 Growth Conference, Sep-21-2016 01:30 PM
Sep 5 16
Helocyte Inc. Presents at Aegis Capital Corp. 2016 Growth Conference, Sep-21-2016 01:30 PM. Venue: The Encore at Wynn Las Vegas, 3131 Las Vegas Blvd, Las Vegas, NV 89109, United States.
Helocyte Presents at 28th Annual ROTH Conference, Mar-15-2016 12:00 PM
Feb 24 16
Helocyte Presents at 28th Annual ROTH Conference, Mar-15-2016 12:00 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Drive, Laguna Niguel, Dana Point, California, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries